Compagnie Lombard Odier SCmA Purchases 16,611 Shares of Zoetis Inc. $ZTS

Compagnie Lombard Odier SCmA lifted its position in shares of Zoetis Inc. (NYSE:ZTS) by 1,661.1% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 17,611 shares of the company’s stock after acquiring an additional 16,611 shares during the quarter. Compagnie Lombard Odier SCmA’s holdings in Zoetis were worth $2,577,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in the company. Savvy Advisors Inc. raised its position in Zoetis by 54.0% in the 2nd quarter. Savvy Advisors Inc. now owns 3,177 shares of the company’s stock valued at $495,000 after buying an additional 1,114 shares during the last quarter. Chicago Partners Investment Group LLC boosted its position in Zoetis by 67.0% during the 2nd quarter. Chicago Partners Investment Group LLC now owns 4,886 shares of the company’s stock worth $750,000 after acquiring an additional 1,961 shares during the last quarter. CIBC Asset Management Inc grew its stake in shares of Zoetis by 4.3% during the 3rd quarter. CIBC Asset Management Inc now owns 251,495 shares of the company’s stock worth $36,745,000 after acquiring an additional 10,434 shares in the last quarter. Nordea Investment Management AB raised its holdings in shares of Zoetis by 10.0% in the second quarter. Nordea Investment Management AB now owns 2,356,166 shares of the company’s stock valued at $368,245,000 after purchasing an additional 214,889 shares during the last quarter. Finally, Ninety One UK Ltd lifted its position in shares of Zoetis by 19.6% in the third quarter. Ninety One UK Ltd now owns 1,119,132 shares of the company’s stock worth $163,751,000 after purchasing an additional 183,686 shares in the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently weighed in on ZTS shares. BTIG Research reaffirmed a “buy” rating and issued a $160.00 target price on shares of Zoetis in a research report on Wednesday, December 3rd. Barclays began coverage on Zoetis in a report on Monday, December 8th. They issued an “equal weight” rating and a $136.00 price objective for the company. Weiss Ratings lowered Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a report on Wednesday, January 28th. The Goldman Sachs Group raised Zoetis to a “buy” rating in a research report on Monday, December 15th. Finally, Morgan Stanley set a $160.00 price target on Zoetis in a research report on Thursday, December 18th. Five research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $152.45.

Zoetis Price Performance

NYSE:ZTS opened at $127.28 on Tuesday. Zoetis Inc. has a 12-month low of $115.25 and a 12-month high of $177.00. The firm has a market capitalization of $56.09 billion, a price-to-earnings ratio of 21.43, a P/E/G ratio of 2.20 and a beta of 0.96. The stock’s 50 day moving average price is $123.96 and its two-hundred day moving average price is $136.01. The company has a quick ratio of 2.28, a current ratio of 3.64 and a debt-to-equity ratio of 1.31.

Zoetis Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 2nd. Shareholders of record on Monday, April 20th will be issued a dividend of $0.53 per share. The ex-dividend date of this dividend is Monday, April 20th. This represents a $2.12 annualized dividend and a yield of 1.7%. Zoetis’s dividend payout ratio (DPR) is currently 35.69%.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.